Sprint Bioscience AB (publ) SPRINT
This picture changes. Follow Sprint Bioscience AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow Sprint Bioscience AB (publ) freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 2 Aug 2026
General analysis — not personal advice.
NEUTRAL
6/10
Confidence
Hold/watch; consider adding only after confirmed new deals or milestones.
The new AI collaboration with Lilly adds validation to the company's approach yet leaves preclinical risk and milestone uncertainty unchanged.
Market sentiment
7/10
↑
Trend: Improving
Sentiment has strengthened further following the new AI partnership, viewed as a quality stamp.
Price context
The share price at 3.6 SEK follows a 15.8 % gain over three months and reflects market approval of the new Lilly collaboration.
Risk assessment
7/10
Dilution:
Medium
Preclinical company; lumpy revenues and ongoing burn
Jurisdiction:
Low
Sweden with stable regulatory framework
Execution:
Medium
Preclinical development and partner dependence
Cash flow:
24 mo
Recent changes
- Q1 reported revenue 0 MSEK (14.1), EBIT -14.3 MSEK (-5.0) and operating cash flow -19.3 MSEK (-5.5) with cash of 108.3 MSEK (18.8).
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Sprint Bioscience AB (publ) is a Swedish biotech company developing preclinical small-molecule programs, mainly in cancer and tumor metabolism. Its model is to create assets early and out-license/sell them to larger pharma partners. The TREX1 program was sold to Gilead with an upfront payment and potential future milestones.
Sector:
Biotech (preclinical oncology drug development)
Type:
Biotech
Next report
26 Aug 2026
Q2
Catalysts
26 Aug 2026
Q2/Half-year report 2026
Medium
Unknown
Authorisation for up to 25 % dilution
Medium
Horizon:
Bull case
Access to Lilly's predictive AI models can accelerate out-licensing and increase potential deal values.
Bear case
Preclinical stage and irregular revenues continue to imply high burn risk and future capital needs.
Signal rationale (informational)
The new AI collaboration with Lilly adds validation to the company's approach yet leaves preclinical risk and milestone uncertainty unchanged.
Recent news
- Sprint Bioscience signed an agreement on 23 July 2026 with Lilly TuneLab granting access to Eli Lilly's AI and machine-learning models to accelerate preclinical development without sharing proprietary data.
Price & valuation
Last close
SEK 3.36
1 week
-3.4 %
3 months
-6.7 %
Exchange
First North
Type
Biotech
Sector
Biotech (preclinical oncology drug development)
This picture changes. Follow Sprint Bioscience AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.